WallStSmart

Intel Corporation (INTC)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 18% more annual revenue ($63.32B vs $53.76B). PFE leads profitability with a 11.8% profit margin vs -5.9%. INTC appears more attractively valued with a PEG of 1.36. PFE earns a higher WallStSmart Score of 55/100 (C).

INTC

Avoid

33

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 4.3Quality: 7.0
Piotroski: 5/9Altman Z: 1.69

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INTCSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$35.50

Current Price

$124.92

$89.42 premium

UndervaluedFair: $35.50Overvalued
PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INTC1 strengths · Avg: 10.0/10
Market CapQuality
$627.85B10/10

Mega-cap, among the largest globally

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

INTC4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-71.7%2/10

Earnings declined 71.7%

Free Cash FlowQuality
$-2.54B2/10

Negative free cash flow — burning cash

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : INTC

The strongest argument for INTC centers on Market Cap. PEG of 1.36 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : INTC

The primary concerns for INTC are Altman Z-Score, Return on Equity, EPS Growth.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

INTC profiles as a turnaround stock while PFE is a value play — different risk/reward profiles.

INTC carries more volatility with a beta of 2.19 — expect wider price swings.

INTC is growing revenue faster at 7.2% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (55/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Intel Corporation

TECHNOLOGY · SEMICONDUCTORS · USA

Intel Corporation is an American multinational corporation and technology company headquartered in Santa Clara, California, in Silicon Valley. It is the world's largest semiconductor chip manufacturer by revenue, and is the developer of the x86 series of microprocessors, the processors found in most personal computers (PCs).

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?